India’s vaccine candidate against Covid-19 demonstrated a strong immune response in its first phase of clinical trials, it was learned here on Thursday.
The possible Covaxin vaccine, developed by the biotechnology company Bharat Biotech, based in the city of Hyderabad, and the Indian Council of Medical Research, is safe and does not generate serious adverse effects in people of all groups, according to the results of the first phase of clinical trials, All India Radio reported.
The Indian Medical Research Council said that the vaccine can be stored at two to eight degrees Celsius, which makes it compatible with the National Immunization Plan.
Covaxin is one of three candidate vaccines against the pandemic caused by the SARS-CoV-2 coronavirus that is being considered for approval for emergency use in India by the national drug regulator.